For RNAi, 2013 proved to be a year largely marked by incremental successes that, while not always the most attention grabbing, reflect the maturity of the gene-silencing technology and have helped it begin to reignite the interest of big pharma in RNA therapeutics.

It was during the past year that RNAi — indeed, RNA therapeutics in general — "have come of age," Regulus Therapeutics CEO Kleanthis Xanthopoulos told Gene Silencing News. "There is no longer skepticism about whether the … approach works."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.